10:47 AM EDT, 09/08/2025 (MT Newswires) -- Boston Scientific ( BSX ) is outperforming the medical technology sector, with growth over the past year driven by its electophysiology business, Oppenheimer said in a Monday note.

"BSX represents one of the best large-cap medtech growth stories, driven by disciplined mergers and acquisitions and strong execution, most obviously in the [electophysiology] franchise," said the investment firm.

The company has several product tailwinds and among its growth catalysts is the Farapoint pulsed field ablation focal catheter system, which is slated for early roll-out in the US in H2, Oppenheimer said.

Oppenheimer upgraded Boston Scientific ( BSX ) to outperform from perform, with a price target of $125.

Price: 107.95, Change: +0.72, Percent Change: +0.68